News

• aTyr Pharma and Lonza Announce Manufacturing Agreement for aTyr’s Anti-NRP2 Antibody ATYR2810
  04/14/2021 / 14:00 - GlobeNewswire
•  
• Altimmune Expands AdCOVID™ Manufacturing Collaboration with Lonza
  03/12/2021 / 07:00 - GlobeNewswire
•  
• Capricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications
  01/12/2021 / 15:05 - GlobeNewswire
•  
• Achilles Therapeutics Appoints Arjan Roozen as VP, Site Head and General Manager
  01/08/2021 / 13:00 - GlobeNewswire
•  
• Arbor Biotechnologies and Lonza Enter into Gene Editing Technology Licensing Deal
  12/23/2020 / 14:00 - GlobeNewswire
•  
• Altimmune Adds Lonza as a Manufacturing Partner for Supply of AdCOVID™ its Single-Dose Intranasal Vaccine Candidate for COVID-19
  11/10/2020 / 07:00 - GlobeNewswire
•  
• Institutional Investor Research Publishes 2020 Europe Executive Team Rankings
  09/04/2020 / 07:00 - GlobeNewswire
•  
• Amarantus Announces Subsidiary MANF Therapeutics Enters Into Material Transfer Agreement with Dyadic International
  02/06/2020 / 14:11 - GlobeNewswire
•  
• Amarantus Releases Letter to Shareholders
  02/04/2020 / 15:54 - GlobeNewswire
•  
• Amarantus Acquires Majority Interest in CBD Wellness Company Hempori
  01/30/2020 / 15:05 - GlobeNewswire
•  
• Amarantus Completes Sublicense of ESS, MANF and PhenoGuard to Emerald Organic Products
  01/02/2020 / 14:14 - GlobeNewswire
•  
• Amarantus to Present at 12th Annual LD Micro Main Event
  12/09/2019 / 14:00 - GlobeNewswire
•  
• Amarantus Subsidiary Elto Pharma Receives Notice of Allowance Covering Use of Eltoprazine Combined with CBD to Treat Parkinson’s Disease
  12/04/2019 / 13:36 - GlobeNewswire
•  
• Amarantus Announces Issuance of Chinese Patent Covering the Use of MANF and CDNF in Retinal Disorders for Subsidiary MANF Therapeutics
  11/21/2019 / 14:00 - GlobeNewswire
•  
• Amarantus Provides Recapitalization Update to Shareholders
  11/18/2019 / 14:30 - GlobeNewswire